SPAA-52

| Cat. No.: | HY-151591 | | |
|--------------------|---|-------|----------|
| CAS No.: | 2837000-75-4 | | |
| Molecular Formula: | C ₈ H ₈ Br ₂ N ₂ O ₄ S | | |
| Molecular Weight: | 388.03 | | |
| Target: | Phosphatase | | |
| Pathway: | Metabolic Enzyme/Protease | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |

®


MedChemExpress

SOLVENT & SOLUBILITY

| | | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|--|------------------------------|-------------------------------|-----------|------------|------------|
| | Preparing Stock Solutions | 1 mM | 2.5771 mL | 12.8856 mL | 25.7712 mL |
| | | 5 mM | 0.5154 mL | 2.5771 mL | 5.1542 mL |
| | | 10 mM | 0.2577 mL | 1.2886 mL | 2.5771 mL |

BIOLOGICAL ACTIVITY

| Description | SPAA-52 is an orally active, competitive and reversible low-molecular-weight protein tyrosine phosphatase (LMW-PTP) inhibitor (IC ₅₀ =4 nM, K _i =1.2 nM). SPAA-52 can be used in diabete research ^[1] . | | | | |
|---------------------------|--|------------|-------------|--|--|
| IC ₅₀ & Target | IC ₅₀ : 4 nM (LMW-PTP) ^[1] | | | | |
| In Vivo | Plasma PK Parameters in Healthy $Mice^{[1]}$ | | | | |
| | Compound | SPAA-52 | | | |
| | dose route | 2 mg/kg IV | 10 mg/kg PO | | |
| | AUC (0–8 h) (nM h) | 15,100 | 37,300 | | |
| | | | | | |



Product Data Sheet

| C ₀ or C _{max} (nM) | 13,400 | 9690 |
|---|--------|------|
| C ₀ or C _{max} unbound (nM) | 332 | 233 |
| Vd _{ss} (L/kg) | 0.42 | |
| CL (mL/min/kg) | 5.65 | |
| T _{1/2} (h) | 1.41 | 4.2 |
| F (%) | | 34 |

Plasma PK Parameters in Healthy Rats^[1]

| Compound | SPAA-52 |
|-------------------------------|------------|
| dose route | 3 mg/kg PO |
| AUC (0-12 h) (nM h) | 4660 |
| C _{max} (nM) | 877 |
| C _{max} unbound (nM) | 21 |
| Vd _{ss} (L/kg) | 0.42 |
| T _{max} (h) | 2.0 |
| T _{1/2} (h) | 2.4 |
| | |

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. He R, et al. Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors. J Med Chem. 2022 Oct 5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA